Show simple item record

dc.contributor.authorUrsprung, Stephan
dc.contributor.authorWoitek, Ramona
dc.contributor.authorMcLean, Mary A
dc.contributor.authorPriest, Andrew N
dc.contributor.authorCrispin-Ortuzar, Mireia
dc.contributor.authorBrodie, Cara R
dc.contributor.authorGill, Andrew B
dc.contributor.authorGehrung, Marcel
dc.contributor.authorBeer, Lucian
dc.contributor.authorRiddick, Antony CP
dc.contributor.authorField-Rayner, Johanna
dc.contributor.authorGrist, James T
dc.contributor.authorDeen, Surrin S
dc.contributor.authorRiemer, Frank
dc.contributor.authorKaggie, Joshua D
dc.contributor.authorZaccagna, Fulvio
dc.contributor.authorDuarte, Joao AG
dc.contributor.authorLocke, Matthew J
dc.contributor.authorFrary, Amy
dc.contributor.authorAho, Tevita F
dc.contributor.authorArmitage, James N
dc.contributor.authorCasey, Ruth
dc.contributor.authorMendichovszky, Iosif A
dc.contributor.authorWelsh, Sarah J
dc.contributor.authorBarrett, Tristan
dc.contributor.authorGraves, Martin J
dc.contributor.authorEisen, Tim
dc.contributor.authorMitchell, Thomas J
dc.contributor.authorWarren, Anne Y
dc.contributor.authorBrindle, Kevin M
dc.contributor.authorSala, Evis
dc.contributor.authorStewart, Grant D
dc.contributor.authorGallagher, Ferdia A
dc.date.accessioned2022-02-21T02:02:39Z
dc.date.available2022-02-21T02:02:39Z
dc.date.issued2022-01-11
dc.identifier.issn2072-6694
dc.identifier.otherPMC8773685
dc.identifier.other35053497
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/334257
dc.description.abstractDifferentiating aggressive clear cell renal cell carcinoma (ccRCC) from indolent lesions is challenging using conventional imaging. This work prospectively compared the metabolic imaging phenotype of renal tumors using carbon-13 MRI following injection of hyperpolarized [1-13C]pyruvate (HP-13C-MRI) and validated these findings with histopathology. Nine patients with treatment-naïve renal tumors (6 ccRCCs, 1 liposarcoma, 1 pheochromocytoma, 1 oncocytoma) underwent pre-operative HP-13C-MRI and conventional proton (1H) MRI. Multi-regional tissue samples were collected using patient-specific 3D-printed tumor molds for spatial registration between imaging and molecular analysis. The apparent exchange rate constant (kPL) between 13C-pyruvate and 13C-lactate was calculated. Immunohistochemistry for the pyruvate transporter (MCT1) from 44 multi-regional samples, as well as associations between MCT1 expression and outcome in the TCGA-KIRC dataset, were investigated. Increasing kPL in ccRCC was correlated with increasing overall tumor grade (ρ = 0.92, p = 0.009) and MCT1 expression (r = 0.89, p = 0.016), with similar results acquired from the multi-regional analysis. Conventional 1H-MRI parameters did not discriminate tumor grades. The correlation between MCT1 and ccRCC grade was confirmed within a TCGA dataset (p < 0.001), where MCT1 expression was a predictor of overall and disease-free survival. In conclusion, metabolic imaging using HP-13C-MRI differentiates tumor aggressiveness in ccRCC and correlates with the expression of MCT1, a predictor of survival. HP-13C-MRI may non-invasively characterize metabolic phenotypes within renal cancer.
dc.languageeng
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101526829
dc.sourceessn: 2072-6694
dc.subjectRenal cell carcinoma
dc.subjectMonocarboxylate transporter
dc.subjectCancer Metabolism
dc.subjectHyperpolarized 13c Magnetic Resonance Imaging
dc.titleHyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study.
dc.typeArticle
dc.date.updated2022-02-21T02:02:39Z
prism.issueIdentifier2
prism.publicationNameCancers (Basel)
prism.volume14
dc.identifier.doi10.17863/CAM.81670
dcterms.dateAccepted2022-01-06
rioxxterms.versionofrecord10.3390/cancers14020335
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidUrsprung, Stephan [0000-0003-2476-178X]
dc.contributor.orcidPriest, Andrew N [0000-0002-9771-4290]
dc.contributor.orcidGill, Andrew B [0000-0002-9287-9563]
dc.contributor.orcidBeer, Lucian [0000-0003-4388-7580]
dc.contributor.orcidDeen, Surrin S [0000-0002-6206-7337]
dc.contributor.orcidRiemer, Frank [0000-0002-3805-5221]
dc.contributor.orcidKaggie, Joshua D [0000-0001-6706-3442]
dc.contributor.orcidZaccagna, Fulvio [0000-0001-6838-9532]
dc.contributor.orcidWelsh, Sarah J [0000-0001-5690-2677]
dc.contributor.orcidEisen, Tim [0000-0001-9663-4873]
dc.contributor.orcidBrindle, Kevin M [0000-0003-3883-6287]
dc.contributor.orcidStewart, Grant D [0000-0003-3188-9140]
dc.contributor.orcidGallagher, Ferdia A [0000-0003-4784-5230]
dc.identifier.eissn2072-6694
pubs.funder-project-idCancer Research Uk (None)
pubs.funder-project-idCancer Research Uk (None)
pubs.funder-project-idCancer Research UK (C12912/A27150)
pubs.funder-project-idWellcome Trust (095962/Z/11/Z)
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
pubs.funder-project-idCancer Research UK (A25117)
pubs.funder-project-idMRC (MR/T024097/1)
pubs.funder-project-idEPSRC (EP/T017961/1)
cam.issuedOnline2022-01-11


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International